ClinicalTrials.gg
Not yet recruitingNCT07944274PRXS-HOME-RCTUpdated Nov 18, 2026

Active Versus Vehicle Home Care During PRX S Treatment for Mild-to-Moderate Facial Acne

An interventional study of PRX S Treatment and Active Balancing Cream in Acne Vulgaris, sponsored by Medical University of Silesia. Not yet recruiting at 2 sites in Poland. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 25 studies in Acne Vulgaris with a site in Poland — 2 open to participants now, 6 under way, 1 of them phase 3. Acne Vulgaris · Poland.

Planned enrollment
15th of 19
50 · median 350
Started
2026
with 2 others
No phase
6 of 25
2 open now
Registered
24th of 25
by date
Lead sponsor
2 of 25
Medical University of Silesia

Among the 25 studies in Acne Vulgaris with a site in Poland, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, and was the 24th registered.

Acne Vulgaris

792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

2 of the 25 studies in Acne Vulgaris with a site in Poland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger; 20 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Acne Vulgaris with a site in Poland, or all of them as a file.
02

Study summary

This prospective, randomized, parallel-group study aims to evaluate the additional effects of active Balancing Cream compared with its vehicle during a standardized series of five PRX S treatments in adults with mild-to-moderate facial acne.

A total of 50 participants aged 18-60 years with dermatologist-confirmed mild-to-moderate facial acne (Investigator's Global Assessment [IGA] grade 2 or 3) will be enrolled and allocated to two groups of 25 participants each.

Both groups will receive five PRX S treatments at 14-day intervals and use the same Nourishing Cream for Normal and Combination Skin in the morning. In the evening, the experimental group will apply active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide, while the comparator group will use a corresponding cream vehicle without these three ingredients.

The primary outcome is the change from baseline in the total number of facial inflammatory lesions (papules and pustules), assessed two weeks after the fifth PRX S treatment. Secondary assessments include acne severity, non-inflammatory lesion counts, skin biophysical and imaging measurements, and treatment safety.

Clinical and instrumental assessments will be performed at baseline (T0), approximately day 42 (T1), approximately day 70 (T2), and two months after T2 (T3).

The study is designed to assess the additional benefit of active Balancing Cream compared with its vehicle under identical PRX S treatment conditions, rather than the independent efficacy of PRX S.

Read the detailed description

This prospective, randomized, two-arm, parallel-group clinical study will investigate whether active Balancing Cream provides additional clinical and instrumental benefits compared with its corresponding vehicle when used as adjunctive home care during a standardized series of five PRX S treatments in adults with mild-to-moderate facial acne.

**Study Design and Participants**

The study will include 50 adults aged 18-60 years with dermatologist-confirmed mild-to-moderate facial acne, defined as Investigator's Global Assessment (IGA) grade 2 or 3 and at least five inflammatory lesions (papules and pustules) on the face.

Following eligibility assessment, written informed consent, and baseline measurements, participants will be randomized in a 1:1 ratio to two parallel treatment groups, with 25 participants planned per group. Randomization is planned using computer-generated permuted blocks of varying sizes, stratified by baseline IGA grade (2 or 3). Allocation concealment and masking procedures will be finalized and approved before enrollment.

**Treatment Groups**

Group A (Experimental): Participants will receive five PRX S treatments and use Nourishing Cream for Normal and Combination Skin in the morning and active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide in the evening.

Group B (Vehicle Comparator): Participants will receive the same five PRX S treatments and use the same Nourishing Cream in the morning and a corresponding Balancing Cream vehicle without azelaic acid, salicylic acid, and niacinamide in the evening.

PRX S will be applied externally to the facial skin on days 0, 14, 28, 42, and 56, according to the manufacturer's instructions and a standardized treatment procedure. Both groups will follow identical cleansing and photoprotection recommendations. Assigned home care will continue from baseline (T0) through the final follow-up visit (T3).

The study interventions differ only in the assigned Balancing Cream formulation. The comparator vehicle is not intended to represent a placebo for the PRX S treatment.

**Assessment Schedule**

Clinical and instrumental assessments will be conducted at four time points:

  • T0: Baseline, before the first PRX S treatment and initiation of assigned home care.
  • T1: Approximately day 42, after three PRX S treatments and before the fourth treatment.
  • T2: Approximately day 70, 14 days after the fifth PRX S treatment.
  • T3: Two calendar months after T2, during continued assigned home care.

**Clinical and Instrumental Assessments**

Clinical evaluations will include counts of inflammatory facial lesions (papules and pustules), non-inflammatory lesions (open and closed comedones), and acne severity according to the IGA scale.

The instrumental assessment panel will include:

  • Antera 3D imaging for prespecified skin pore, texture, and roughness parameters.
  • Standardized facial photography using Fotomedicus.
  • Sebumetry to evaluate skin sebum levels.
  • Corneometry to assess skin hydration.
  • Cutometry to evaluate skin elasticity, including the R2 parameter.
  • Skin ultrasonography to assess dermal thickness and echogenicity.

Measurements will be performed on predefined facial areas under standardized conditions.

**Primary Outcome and Statistical Analysis**

The primary outcome is the individual change in total facial inflammatory lesion count from baseline (T0) to T2, calculated as the number of papules and pustules at T2 minus the corresponding baseline count.

The primary analysis will compare the experimental and vehicle groups using analysis of covariance (ANCOVA), adjusting for baseline inflammatory lesion count and baseline IGA stratum (2 or 3).

A negative adjusted difference between the experimental and comparator groups will favor the active Balancing Cream.

Secondary outcomes will include changes in non-inflammatory lesion counts, percentage reduction in inflammatory lesions, IGA scores and response rates, longitudinal skin biophysical parameters, imaging measurements, and safety outcomes. Secondary analyses will be exploratory.

**Safety Monitoring**

Treatment tolerability, adverse events, adherence to assigned home care, and concomitant acne treatments will be monitored throughout the study.

Participants experiencing clinically significant irritation, allergic reactions, infection, or acne worsening will undergo dermatological assessment. Treatment interruption, discontinuation, or rescue therapy will be implemented when clinically indicated.

The study will evaluate the added effect of the three ingredients present in active Balancing Cream within a common PRX S treatment and home-care regimen. It is not designed to determine the independent efficacy of PRX S compared with no PRX S treatment.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Mild-to-moderate facial acne
  • Inflammatory lesion count
  • Azelaic acid
  • Salicylic acid
  • Niacinamide
  • PRX S
  • Balancing Cream
  • Skin hydration
  • Sebum production
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-60 years.
  • Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
  • Presence of at least five countable inflammatory facial acne lesions (papules and pustules).
  • Written to participate in the study and undergo study-related documentation.
  • No to the study interventions, with clinical suitability confirmed by a dermatologist.
  • Ability and willingness to comply with scheduled study visits and assigned home-care procedures.
  • No immediate need for alternative acne treatment that is not provided within the study protocol.

Exclusion criteria

Exclusion Criteria:

  • IGA grade 0, 1, or 4.
  • Severe or nodulocystic acne, or rapidly progressive acne scarring.
  • Pregnancy or breastfeeding.
  • Known or allergy to any ingredient of the study products.
  • Active skin infections, including herpes simplex, open wounds, erosions, or burns in the treatment area.
  • Active atopic dermatitis, seborrheic dermatitis, or other dermatological conditions that could interfere with study assessments.
  • Malignant or suspicious skin lesions in the treatment area.
  • diseases or treatments that may increase the risk associated with study interventions or interfere with study outcomes.
  • Use of topical retinoids within 30 days before baseline (T0).
  • Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
  • Completion of isotretinoin treatment less than 6 months before baseline (T0).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    PRX S + Active Balancing Cream

    Participants in this arm will receive five PRX S treatments applied to the facial skin at 14-day intervals (days 0, 14, 28, 42, and 56). In addition, participants will use Nourishing Cream for Normal and Combination Skin in the morning and active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide in the evening, from baseline (T0) through the final follow-up visit (T3).

    Procedure: PRX S Treatment · Other: Active Balancing Cream · Other: Nourishing Cream for Normal and Combination Skin

  • Placebo comparator
    PRX S + Balancing Cream Vehicle

    Participants in this arm will receive the same five PRX S treatments applied to the facial skin at 14-day intervals (days 0, 14, 28, 42, and 56). Participants will use the same Nourishing Cream for Normal and Combination Skin in the morning and a corresponding Balancing Cream vehicle without azelaic acid, salicylic acid, and niacinamide in the evening, from baseline (T0) through the final follow-up visit (T3). The vehicle serves as a comparator for the active Balancing Cream, not for PRX S treatment.

    Procedure: PRX S Treatment · Other: Balancing Cream Vehicle · Other: Nourishing Cream for Normal and Combination Skin

Interventions

  • ProcedurePRX S Treatment

    PRX S is a professional topical treatment applied to the facial skin after product activation according to the manufacturer's instructions and a standardized procedure. Participants will receive five treatment sessions at 14-day intervals on days 0, 14, 28, 42, and 56. The same PRX S treatment protocol will be used in both study arms.

  • OtherActive Balancing Cream

    Active Balancing Cream is a topical facial cream containing azelaic acid, salicylic acid, and niacinamide. Participants assigned to the experimental arm will apply the cream to the facial skin in the evening as part of their home-care regimen, from baseline (T0) through the final follow-up visit (T3). The cream will be used alongside five PRX S treatments and morning application of Nourishing Cream for Normal and Combination Skin.

  • OtherBalancing Cream Vehicle

    Balancing Cream Vehicle is a corresponding topical facial cream formulation without azelaic acid, salicylic acid, and niacinamide. Participants assigned to the comparator arm will apply the vehicle to the facial skin in the evening as part of their home-care regimen, from baseline (T0) through the final follow-up visit (T3). The vehicle will be used alongside five PRX S treatments and morning application of Nourishing Cream for Normal and Combination Skin.

  • OtherNourishing Cream for Normal and Combination Skin

    Nourishing Cream for Normal and Combination Skin is a topical facial moisturizer used as standardized morning home care in both study arms. Participants will apply the cream in the morning from baseline (T0) through the final follow-up visit (T3), alongside their assigned evening Balancing Cream formulation and five PRX S treatments.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Facial Inflammatory Lesion Count

    Absolute individual change in the total number of facial inflammatory lesions (papules and pustules), calculated as the lesion count at T2 minus the baseline count at T0. The unit of measurement is number of lesions. Negative values indicate improvement. The primary comparison between active Balancing Cream and vehicle groups will use ANCOVA adjusted for baseline inflammatory lesion count and baseline IGA stratum (2 or 3).

    Time frame: Baseline (Day 0) and 2 weeks after the fifth PRX S treatment (approximately Day 70).

Secondary outcomes

  1. Change From Baseline in Facial Non-Inflammatory Lesion Count

    Change from baseline in the total number of facial non-inflammatory acne lesions, including open and closed comedones. The unit of measurement is number of lesions.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  2. Percentage Reduction in Facial Inflammatory Lesion Count

    Percentage reduction in the total number of facial papules and pustules relative to baseline, calculated as 100 × (baseline lesion count - follow-up lesion count) / baseline lesion count.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  3. Change From Baseline in Facial Inflammatory Lesion Count at Day 42 and Final Follow-Up

    Absolute change in the total number of facial inflammatory lesions (papules and pustules) from baseline to T1 and T3. The unit of measurement is number of lesions. Negative values indicate improvement.

    Time frame: Baseline (Day 0), approximately Day 42, and 2 calendar months after the Day 70 assessment.

  4. Investigator's Global Assessment (IGA) of Acne Severity

    Facial acne severity assessed using the Investigator's Global Assessment (IGA), an ordinal scale from 0 to 4. The distribution of IGA grades and changes over time will be evaluated.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  5. Proportion of Participants Achieving IGA Grade 0 or 1

    Percentage of participants achieving an Investigator's Global Assessment (IGA) grade of 0 or 1 at each follow-up assessment.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  6. Proportion of Participants Achieving IGA Treatment Success

    Percentage of participants achieving an IGA grade of 0 or 1 together with an improvement of at least 2 grades from baseline. Results will be described according to baseline IGA grade (2 or 3).

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  7. Change From Baseline in Facial Skin Sebum Level

    Skin sebum level measured by sebumetry in standardized facial areas. Results will be expressed in micrograms per square centimeter (µg/cm²).

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  8. Change From Baseline in Skin Hydration

    Skin hydration assessed by corneometry in standardized facial areas. Results will be expressed in arbitrary units.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  9. Change From Baseline in Skin Elasticity (Cutometer R2)

    Skin elasticity assessed using the Cutometer R2 parameter in standardized facial areas. R2 is a dimensionless measurement.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  10. Change From Baseline in Dermal Thickness

    Dermal thickness assessed by skin ultrasonography in standardized facial areas. Results will be expressed in millimeters (mm).

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  11. Change From Baseline in Dermal Echogenicity

    Dermal echogenicity assessed by skin ultrasonography under standardized measurement settings. Results will be expressed in arbitrary units.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  12. Incidence of Adverse Events During Treatment and Follow-Up

    Number and percentage of participants experiencing adverse events, including local skin reactions and acne worsening. Adverse event severity, seriousness, relationship to study interventions, treatment interruptions, discontinuations, and rescue therapy will be recorded.

    Time frame: From the first study intervention (Day 0) through the final follow-up visit, approximately 2 calendar months after Day 70.

  13. Change From Baseline in Facial Skin Pore Parameters Assessed by Antera 3D

    Changes in facial skin pore parameters assessed using Antera 3D imaging in standardized facial areas at baseline and follow-up visits. The assessment will use prespecified Antera 3D pore-related outputs.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  14. Change From Baseline in Facial Skin Texture Assessed by Antera 3D

    Changes in facial skin texture assessed by Antera 3D imaging in standardized facial areas. Measurements will be performed at baseline and scheduled follow-up visits using prespecified skin texture parameters.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  15. Change From Baseline in Facial Skin Roughness Assessed by Antera 3D

    Changes in facial skin roughness assessed using Antera 3D imaging in standardized facial areas at baseline and follow-up visits. The assessment will use prespecified Antera 3D roughness parameters.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

  16. Standardized Facial Photography Using Fotomedicus

    Standardized facial photographs will be obtained using the Fotomedicus system at baseline and scheduled follow-up visits to document facial skin appearance and visible acne lesions over time.

    Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.

07

Study locations

2 sites
  • AJ Med
    Mysłowice, Poland
  • Department of Practical Cosmetology and Skin Diagnostics, Medical University of Silesia
    Sosnowiec, 41-208, Poland
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data and the accompanying data dictionary will be made available to researchers upon reasonable request, subject to participant consent and the applicable data-sharing policies of the Medical University of Silesia in Katowice.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Following publication of the study results, with no predetermined end date for considering data access requests.

Access criteria: Access to de-identified individual participant data and the data dictionary will be considered upon reasonable request, subject to participant consent and the applicable policies of the Medical University of Silesia in Katowice.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 58 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's planned 3 months is below that.

Counting every sponsor, half of 120 studies reached it within 9 months; a quarter within 4 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
May 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944274
Collaborators
WiQo S.p.A.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Anna Deda, PhD
Contact
adeda@sum.edu.pl
+48 500 233 457
Anna Deda, PhD
principal investigator · Medical University of Silesia in Katowice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion